Bladder Cancer

Bladder Cancer

Low Grade NMIBC (Non-Muscle Invasive Bladder Cancer)

TC-BC-12: The Efficacy and Safety of UGN-102 as a Primary Chemoablative Therapy in Patients With LG NMIBC at Intermediate Risk of Recurrence

Phase: 2
Study Product: UGN-102
Estimated Study Completion Date: September 2020
ClinicalTrials.gov Identifier: NCT03558503


HR NMIBC Post BCG

KEYNOTE-676: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in HR NMIBC

Phase: 3
Study Product: Pembrolizumab with BCG
Estimated Study Completion Date: November 25, 2024
ClinicalTrials.gov Identifier: NCT03711032


KEYNOTE-057: Study of Pembrolizumab (MK-3475) in Participants With HR NMIBC

Phase: 2
Study Product: Pembrolizumab
Estimated Study Completion Date: July 30, 2023
ClinicalTrials.gov Identifier: NCT02625961


CheckMate 9UT: A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without BCG in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Phase: 2
Study Product: Nivolumab vs. Nivolumab with BCG vs. Nivolumab with BMS-986205 vs. Nivolumab with BMS-986205 with BCG
Estimated Study Completion Date: April 16, 2023
ClinicalTrials.gov Identifier: NCT03519256


HR NMIBC or MIBC Pre or Post BCG

NanoDoce: Evaluation of NanoDoce in Subjects with Urothelial Carcinoma

Phase: 1/2
Study Product: NanoDoce Injection with NanoDoce Intravesical Instillation vs. NanoDoce Injection with Standard of Care
Estimated Study Completion Date: November 2020
ClinicalTrials.gov Identifier: NCT03636256


KEYNOTE-905: Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer

Phase: 3
Study Product: Pembrolizumab with Radical Cystectomy plus Pelvic Lymph Node Dissection vs. Radical Cystectomy plus Pelvic Lymph Node Dissection
Estimated Study Completion Date: February 16, 2026
ClinicalTrials.gov Identifier: NCT03924895


Advanced/Metastatic Urothelial Carcinoma (UC)

FIGHT-201: A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma

Phase: 2
Study Product: Pemigatinib
Estimated Study Completion Date: January 2020
ClinicalTrials.gov Identifier: NCT02872714


Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Jennifer at (843) 449-1010 ext. 316 or email us by filling out the form below.


Please fill in the form below to email us to learn more about our trials: